Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed attachment file name file name title title grouped question UIN question first answered answering member label
tabling member	label

Search

175896

registered interest
date	27/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what was the total level of spending incurred by the Cancer Drugs Fund on reimbursing the National Health Service for molecular diagnostics testing in the last three years for which figures are available.
tabling member printed	Lord Hunt of Kings Heath
uin	HL4476
answer	answer is ministerial correction date of answer 04/02/2015 answer text <p>Information on expenditure by the Cancer Drugs Fund (CDF) prior to 1 April 2013 is not available at individual drug/indication level.</p><p> </p><p> </p><p> </p><p>NHS England has had oversight of the Fund since April 2013 and publishes information on the Fund’s financial position on its website at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/pe/cdf/" target="_blank">www.england.nhs.uk/ourwork/pe/cdf/</a></p><p> </p><p> </p><p> </p><p>This is also attached.</p><p> </p><p> </p><p> </p><p>Only one type of molecular diagnostic has been funded through the CDF since NHS England took over operational management of the Fund in April 2013. RAS (rat <a title="Sarcoma" href="http://en.wikipedia.org/wiki/Sarcoma" target="_blank">sarcoma</a>) testing can be funded though the CDF as a temporary measure while work is currently underway to clarify legacy arrangements for how such tests are currently commissioned and ensure alignment with the National Tariff payment rules.</p><p> </p><p> </p><p> </p><p>NHS England has advised that it is currently receiving approximately 350 notifications per month for RAS testing at an estimated cost of £70,000 per month.</p><p> </p> answering member printed Earl Howe attachment 1 file name HL4476 2013-14.pdf title CDF Summary Financial Report - Month 9 2 file name HL4476 2013-14 final.pdf title CDF Summary Financial Report question first answered 04/02/2015 13:53:49 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

175897

registered interest
date	27/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what proportion of the Cancer Drugs Fund budget has been allocated for molecular diagnostic testing costs in 2015–16.
tabling member printed	Lord Hunt of Kings Heath
uin	HL4477
answer	answer is ministerial correction date of answer 04/02/2015 answer text <p>NHS England has advised that the Cancer Drugs Fund budget for 2015-16 is not broken down at individual drug/indication level.</p><p> </p> answering member printed Earl Howe question first answered 04/02/2015 13:54:02 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

175898

registered interest
date	27/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what processes have been put in place to ensure equitable access to molecular diagnostics across the National Health Service for medicines listed on the Cancer Drugs Fund.
tabling member printed	Lord Hunt of Kings Heath
uin	HL4478
answer	answer is ministerial correction date of answer 04/02/2015 answer text <p>NHS England has advised that it is not the sole commissioner of molecular diagnostic testing.</p><p> </p><p> </p><p> </p><p>Work is currently underway to clarify legacy arrangements for how such tests are currently commissioned and ensure alignment with the National Tariff payment rules. It is NHS England’s intention to ensure that a whole systems approach to the future commissioning of diagnostics within specialised services and by clinical commissioning groups forms part of a clinical and scientific strategy informing new models of care and the implementation of the Five Year Forward View.</p><p> </p> answering member printed Earl Howe question first answered 04/02/2015 13:54:38 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

175899

registered interest
date	27/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government which National Health Service trusts have applied for reimbursement of molecular diagnostics for medicines listed on the Cancer Drugs Fund in the last year for which figures are available.
tabling member printed	Lord Hunt of Kings Heath
uin	HL4479
answer	answer is ministerial correction date of answer 04/02/2015 answer text <p>NHS England has advised that this information is not collected centrally.</p><p> </p> answering member printed Earl Howe question first answered 04/02/2015 13:54:54 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

175900

registered interest
date	27/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what guidance is being provided to National Health Service trusts regarding the option to recoup the costs of molecular diagnostics for medicines listed on the Cancer Drugs Fund.
tabling member printed	Lord Hunt of Kings Heath
uin	HL4480
answer	answer is ministerial correction date of answer 04/02/2015 answer text <p>NHS England’s standard operating procedures for the Cancer Drugs Fund set out the basis on which the Cancer Drugs Fund operates. They are attached and also available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2014/11/sop-cdf-1114.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2014/11/sop-cdf-1114.pdf</a></p><p> </p> answering member printed Earl Howe question first answered 04/02/2015 13:55:25 answering member 2000 label Biography information for Earl Howe attachment 1 file name CDF Standard Operating Procedures.pdf title CDF Standard Operating Procedures
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

175405

registered interest
date	23/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Gastrointestinal Cancer: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government why the Cancer Drugs Fund has classified gastrointestinal stromal tumours as a normal cancer rather than a rare cancer in relation to its appraisal of regorafenib.
tabling member printed	Lord Hunt of Kings Heath
uin	HL4391
answer	answer is ministerial correction date of answer 03/02/2015 answer text <p>The Cancer Drugs Fund has not classed gastrointestinal stromal tumours as a normal cancer and recognises it as a rare cancer. However, it does not recognise regorafenib as a drug that treats rare cancers alone as it has a European licence for bowel cancer.</p><p> </p> answering member printed Earl Howe question first answered 03/02/2015 13:56:53 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

175406

registered interest
date	23/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government how many drug companies agreed to make appropriate adjustment to their prices to allow their drugs to stay in the Cancer Drugs Fund.
tabling member printed	Lord Hunt of Kings Heath
uin	HL4392
answer	answer is ministerial correction date of answer 03/02/2015 answer text <p>A number of companies made an adjustment, but the precise number is considered to be commercially confidential.</p><p> </p> answering member printed Earl Howe question first answered 03/02/2015 13:56:28 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

175407

registered interest
date	23/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government which companies refused to make appropriate adjustment to their prices to allow their drugs to stay in the Cancer Drugs Fund.
tabling member printed	Lord Hunt of Kings Heath
uin	HL4393
answer	answer is ministerial correction date of answer 04/02/2015 answer text <p>We cannot provide this information as information of this nature is commercial in confidence.</p><p> </p> answering member printed Earl Howe grouped question UIN HL4395 question first answered 04/02/2015 13:50:44 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

175408

registered interest
date	23/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether the Cancer Drugs Fund is to continue to fund any drugs where the appropriate company refused to make appropriate adjustment to their prices and where it failed to meet the value for money test.
tabling member printed	Lord Hunt of Kings Heath
uin	HL4394
answer	answer is ministerial correction date of answer 04/02/2015 answer text <p>A drug may be funded in exceptional circumstances via the individual funding route. In addition, a drug may be retained in the Cancer Drugs Fund in an indication where it provides greater clinical benefit than the indication for which it has been removed.</p><p> </p> answering member printed Earl Howe question first answered 04/02/2015 13:51:05 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

175409

registered interest
date	23/01/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Gastrointestinal Cancer: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether Bayer made any approach to the Cancer Drug Fund to offer to reduce their price for the use of regorafenib as a third line drug for people with gastrointestinal stromal tumours.
tabling member printed	Lord Hunt of Kings Heath
uin	HL4395
answer	answer is ministerial correction date of answer 04/02/2015 answer text <p>We cannot provide this information as information of this nature is commercial in confidence.</p><p> </p> answering member printed Earl Howe grouped question UIN HL4393 question first answered 04/02/2015 13:50:44 answering member 2000 label Biography information for Earl Howe
tabling member	2024 label Biography information for Lord Hunt of Kings Heath